Global Precocious Puberty Treatment Market Size, Share & Trends Analysis Report By Type, By Treatment, By End User, By Region, And Segment Forecasts, 2024 – 2031
Market Overview
The global precocious puberty treatment market reached US$ 1.7 billion in 2023 and is expected to reach US$ 3.1 billion by 2031 growing with a CAGR of 7.6% during the forecast period 2024-2031.
Precocious puberty is defined as the premature onset of puberty in children, characterized by the development of secondary sexual characteristics before the age of 9 in boys and 8 in girls.
The symptoms vary depending on the patient’s gender, girls may experience breast development, menstruation, and rapid growth, while boys might show enlarged testicles and penis, facial hair expansion, and a deepening voice. Additionally, other common indications include bone growth, which might also lead to shorter adult height.
Market Scope
| Metrics | Details |
| CAGR | 7.6% |
| Size Available for Years | 2022-2031 |
| Forecast Period | 2024-2031 |
| Data Availability | Value (US$ Mn) |
| Segments Covered | Type, Treatment, End User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Others key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers
Increasing Research & Development and Product Approvals
The global precocious puberty treatment market has witnessed significant growth due to various recent research and developments. Precocious puberty is usually diagnosed based on medical history and clinical and imaging findings. Also, advanced research and developments in treating precocious puberty drive this market growth.
According to Springer Journal, an article entitled Effect of gonadotropin-releasing hormone agonist monotherapy and combination therapy with growth hormone on final adult height in girls with central precocious puberty published in January 2022 states that GnRHa is a standard treatment for CPP in both boys and girls. It is known to suppress the secretion of sex hormones to slow puberty and suppress rapid bone fusion to achieve final adult height within the growth hormone range.
Moreover, key players in the industry launched innovative drugs that would drive this market growth. For instance, in February 2022, BDR Pharmaceuticals launched its brand ENZALUTAMIDE in 160mg with the brand name BDENZA for Prostate Cancer patients. This medicine was previously available in 40mg and 80mg strength for which patients had to consume two tablets a day as per approved dosage.
Restraints
Factors such as the high cost of the treatment, side effects associated with the treatment of drugs, lack of awareness among people, and stringent regulatory approvals, are expected to hamper the market.
Segment Analysis
The global precocious puberty treatment market is segmented based on type, treatment, end-user, and region.
The medications segment accounted for approximately 55.3% of the global precocious puberty treatment market share
The medications segment is expected to hold the largest market share over the forecast period. The rising clinical trials of drugs globally have contributed to the growing demand for precocious puberty treatment.
According to clinicalTrials.gov, in August. 2023, Foresee Pharmaceuticals Co., Ltd. In collaboration with GeneScience Pharmaceuticals Co., Ltd. conducted a clinical trial to evaluate the efficacy, safety, and pharmacokinetics of leuprolide mesylate in subjects with Central Precocious Puberty.
Moreover, key players' ongoing research studies in the treatment of precocious puberty and launching new drugs would drive this market growth. For instance, in March 2023, Takeda Pharmaceuticals conducted an interventional study of Leuprolide Acetate Depot in children with central precocious puberty. The main aim is to check how leuprolide works to treat central precocious puberty in children.
Also, in March 2022, Accord BioPharma announced the U.S. launch of CAMCEVI (Leuprolide) injection emulsion for the treatment of advanced prostate cancer in adults.
Geographical Analysis
North America accounted for approximately 43.2% of the global precocious puberty market share
North America region is expected to hold the largest market share over the forecast period owing to the rising incidence of precocious puberty, advancements in medical research & technology would drive this market growth.
According to a study published in the Journal of Clinical Endocrinology & Metabolism, in May 2023, the incidence of central precocious puberty in North America has been steadily increasing, with a prevalence of approximately 1 in 5,000 to 1 in 10,000 children. It is estimated that approximately 80% - 90% of CPP cases are idiopathic, especially in females, with a female-to-male ratio of around 20: 1.
Moreover, major key players' presence, well-advanced healthcare system, growing healthcare expenditure, and government support & funding in the development of drugs propel this market growth. For instance, in October 2023, Foresee Pharmaceuticals announced the first patient dosed in the Caspian, phase 3 clinical trial of leuprolide (fp-001) injectable emulsion, 42 mg for the treatment of central precocious puberty patients.
Market Segmentation
By Type
- Central Precocious Puberty
- Peripheral Precocious Puberty
By Treatment
- Medications
- Leuprolide Acetate
- Triptorelin
- Histrelin Acetate
- Nafarelin
- Others
- Surgery
- Others
By End User
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Home Care
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Competitive Landscape
The major global players in the precocious puberty treatment market include Pfizer Inc., Bachem A.G, Aspen API, Sanofi S.A, Piramal Solutions, Anygen Co. Ltd, Sigma Aldrich, Ferring Pharmaceuticals, LGM Pharma, and AmbioPharm among others.
Key Developments
- In April 2024, Foresee Pharmaceuticals Receives a Positive Recommendation from DSMB to Continue the Caspian Study, a Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion for the Treatment of Central Precocious Puberty.
- In January 2024, BDR Pharmaceuticals launches BDENZA a prostate cancer drug in oral solution form. The formulation provides an effective dosage form, with fewer side effects in comparison to existing oral dosage forms of enzalutamide.
Why Purchase the Report?
- To visualize the global precocious puberty treatment market segmentation based on type, treatment, end-user, and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of global precocious puberty treatment market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global precocious puberty treatment market report would provide approximately 62 tables, 57 figures, and 181 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
